{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:40:57Z","timestamp":1773290457327,"version":"3.50.1"},"reference-count":54,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.49","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T23:13:54Z","timestamp":1403046834000},"page":"49-57","source":"Crossref","is-referenced-by-count":15,"title":["The Role of Tumor-Associated Macrophages on Serum Soluble IL-2R Levels in B-Cell Lymphomas"],"prefix":"10.3960","volume":"54","author":[{"given":"Akira","family":"Sakai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Rubin LA, Galli F, Greene WC, Nelson DL, Jay G: The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 2:330-336, 1990","DOI":"10.1016\/1043-4666(90)90062-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Yasuda N, Lai PK, Ip SH, Kung PC, Hinuma Y, <I>et al<\/I>.: Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. Blood 71:1021-1026, 1988","DOI":"10.1182\/blood.V71.4.1021.bloodjournal7141021"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kamihira S, Atogami S, Sohda H, Momita S, Yamada Y, <I>et al<\/I>.: Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia. Cancer 73:2753-2758, 1944","DOI":"10.1002\/1097-0142(19940601)73:11<2753::AID-CNCR2820731117>3.0.CO;2-X"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Ennishi D, Yokoyama M, Terui Y, Asai H, Sakajiri S, <I>et al<\/I>.: Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy. Ann Oncol 20:526-533, 2009","DOI":"10.1093\/annonc\/mdn677"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Goto N, Tsurumi H, Goto H, Shimomura YI, Kasahara S, <I>et al<\/I>.: Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens. Ann Hematol 91:705-714, 2012","DOI":"10.1007\/s00277-011-1363-4"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, <I>et al<\/I>.: Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol 30:1635-1640, 2012","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993","DOI":"10.1056\/NEJM199309303291402"},{"key":"8","unstructured":"8 Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, <I>et al<\/I>.: Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27:4555-4562, 2009"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Morgan DA, Ruscetti FW, Gallo R: Selective <I>in vitro<\/I> growth of T lymphocytes from normal human bone marrow. Science 193:1007-1008, 1976","DOI":"10.1126\/science.181845"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Bayer AL, Yu A, Adeegbe D, Malek TR: Essential role for interleukin-2 for CD4<SUP>+<\/SUP> CD25<SUP>+<\/SUP> T regulatory cell development during the neonatal period. J Exp Med 201:769-777, 2005","DOI":"10.1084\/jem.20041179"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6:1142-1151, 2005","DOI":"10.1038\/ni1263"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Malek TR: The biology of interleukin-2. Annu Rev Immunol 26:453-479, 2008","DOI":"10.1146\/annurev.immunol.26.021607.090357"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Furtado GC, Curotto de Lafaille MA, Kutchukhidze N, Lafaille JJ: Interleukin 2 signaling is required for CD4<SUP>+<\/SUP> regulatory T cell function. J Exp Med 196:851-857, 2002","DOI":"10.1084\/jem.20020190"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Almeida AR, Legrand N, Papiernik M, Freitas AA: Homeostasis of peripheral CD4<SUP>+<\/SUP> T cells: IL-2R&alpha; and IL-2 shape a population of regulatory cells that controls CD4<SUP>+<\/SUP> T cell numbers. J Immunol 169:4850-4860, 2002","DOI":"10.4049\/jimmunol.169.9.4850"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Curotto de Lafaille MA, Lino AC, Kutchukhidze N, Lafaille JJ: CD25<SUP>-<\/SUP> T cells generate CD25<SUP>+<\/SUP> Foxp3<SUP>+<\/SUP> regulatory T cells by peripheral expansion. J Immunol 173:7259-7268, 2004","DOI":"10.4049\/jimmunol.173.12.7259"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Setoguchi R, Hori S, Takahashi T, Sakaguchi S: Homeostatic maintenance of natural Foxp3<SUP>+<\/SUP> CD25<SUP>+<\/SUP> CD4<SUP>+<\/SUP> regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 201:723-735, 2005","DOI":"10.1084\/jem.20041982"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kim HP, Imbert J, Leonard WJ: Both integrated and differential regulation of components of the IL-2\/IL-2 receptor system. Cytokine Growth Factor Rev 17:349-366, 2006","DOI":"10.1016\/j.cytogfr.2006.07.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Leonard WJ: Cytokines and immunodeficiency disease. Nat Rev Immunol 1:200-208, 2001","DOI":"10.1038\/35105066"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Liao W, Lin JX, Leonard W: IL-2 family cytokines: new insights into complex roles of IL-2 as a broad regulator of T helper cell differentiation. Cur Opin Immunol 23:598-604, 2011","DOI":"10.1016\/j.coi.2011.08.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Rochman Y, Spolski R, Leonard WJ: New insights into the regulation of T cells by &gamma;<SUB>c<\/SUB> family cytokines. Nat Rev Immunol 9:480-490, 2009","DOI":"10.1038\/nri2580"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Blackman MA, Tigges MA, Minie ME, Koshland ME: A model system for peptide hormone action in differentiation: interleukin 2 induces a B lymphoma to transcribe the J chain gene. Cell 47:609-617, 1986","DOI":"10.1016\/0092-8674(86)90625-2"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Henney CS, Kuribayashi K, Kern DE, Gillis S: Interleukin-2 augments natural killer cell activity. Nature 291:335-338, 1981","DOI":"10.1038\/291335a0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Friedmann MC, Migone TS, Russell SM, Leonard WJ: Different interleukin 2 receptor beta-chain tyrosines couple to at least two signal pathways and synergistically mediate interleukin 2-induced proliferation. Proc Natl Acad Sci U S A 93:2077-2082, 1996","DOI":"10.1073\/pnas.93.5.2077"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, <I>et al<\/I>.: The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2:331-339, 1995","DOI":"10.1016\/1074-7613(95)90141-8"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Murakami S: Soluble interleukin-2 receptor in cancer. Front Biosci 9:3085-3090, 2004","DOI":"10.2741\/1461"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Witkowska AM: On the role of sIL-2R measurements in rheumatoid arthritis and cancers. Mediators Inflamm 2005:121-130, 2005","DOI":"10.1155\/MI.2005.121"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, <I>et al<\/I>.: Soluble IL-2R&alpha; facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 118:2809-2820, 2011","DOI":"10.1182\/blood-2011-03-340885"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, <I>et al<\/I>.: Clinical significance of sIL-2R levels in B-cell lymphomas. Plos One 11: e78730, 2013","DOI":"10.1371\/journal.pone.0078730"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM: Intratumoral CD4<SUP>+<\/SUP> CD25<SUP>+<\/SUP> regulatory T-cell-mediated suppression of infiltrating CD4<SUP>+<\/SUP> T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006","DOI":"10.1182\/blood-2005-08-3376"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH: Follicular lymphoma intratumoral CD4<SUP>+<\/SUP> CD25<SUP>+<\/SUP> GITR<SUP>+<\/SUP> regulatory T cells potently suppress CD3\/CD28-costimulated autologous and allogeneic CD8<SUP>+<\/SUP> CD25<SUP>-<\/SUP> and CD4<SUP>+<\/SUP> CD25<SUP>-<\/SUP> T cells. J Immunol 178:4051-4061, 2007","DOI":"10.4049\/jimmunol.178.7.4051"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Levine SJ: Mechanisms of soluble cytokine receptor generation. J Immunol 173:5343-5348, 2004","DOI":"10.4049\/jimmunol.173.9.5343"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161-174, 2002","DOI":"10.1038\/nrc745"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141:52-67, 2010","DOI":"10.1016\/j.cell.2010.03.015"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Stetler-Stevenson M, Mansoor A, Lim M, Fukushima P, Kehrl J, <I>et al<\/I>.: Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in reactive and neoplastic lymphoid cells. Blood 89:1708-1715, 1997","DOI":"10.1182\/blood.V89.5.1708.1708_1708_1715"},{"key":"35","unstructured":"35 Hayashibara T, Yamada Y, Onimaru Y, Tsutsumi C, Nakayama S, <I>et al<\/I>.: Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion. Br J Haematol 116:94-102, 2002"},{"key":"36","unstructured":"36 Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, <I>et al<\/I>.: Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness. Blood 99:1341-1349, 2002"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Redondo-Mu&#xF1;oz J, Escobar-D&#237;az E, Samaniego R, Terol MJ, Garc&#237;a-Marco JA, <I>et al<\/I>.: MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood 108:3143-3151, 2006","DOI":"10.1182\/blood-2006-03-007294"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Pennanen H, Kuittinen O, Soini Y, Turpeenniemi-Hujanen T: Prognostic significance of p53 and matrix metalloproteinase-9 expression in follicular lymphoma. Eur J Haematol 81:289-297, 2008","DOI":"10.1111\/j.1600-0609.2008.01113.x"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Redondo-Mu&#xF1;oz J, Ugarte-Berzal E, Terol MJ, Van den Steen PE, Hern&aacute;ndez del Cerro M, <I>et al<\/I>.: Matrix metalloproteinase-9 promotes chronic lymphocytic leukemia B cell survival through its hemopexin domain. Cancer Cell 17:160-172, 2010","DOI":"10.1016\/j.ccr.2009.12.044"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Bingle L, Brown NJ, Lewis CE: The role of tumor-associated macrophages in tumor progression: implications for new anticancer therapies. J Pathol 196:254-265, 2002","DOI":"10.1002\/path.1027"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Mantovani A, Sozzani S, Locati M, Allavena P, Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23:549-555, 2002","DOI":"10.1016\/S1471-4906(02)02302-5"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Gordon S: Alternative activation of macrophages. Nat Rev Immunol 3:23-35, 2003","DOI":"10.1038\/nri978"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 27:451-483, 2009","DOI":"10.1146\/annurev.immunol.021908.132532"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Qian BZ, Pollard JW: Macrophage diversity enhances tumor progression and metastasis. Cell 141:39-51, 2010","DOI":"10.1016\/j.cell.2010.03.014"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Kunisch E, Fuhrmann R, Roth A, Winter R, Lungershausen W, <I>et al<\/I>.: Macrophage specificity of three anti-CD68 monoclonal anti-bodies (KP1, EBM11, and PGM1) widely used for immunohistochemistry and flow cytometry. Ann Rheum Dis 63:774-784, 2004","DOI":"10.1136\/ard.2003.013029"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Clear AJ, Lee AM, Calaminici M, Ramsay AG, Morris KJ, <I>et al<\/I>.: Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163<SUP>+<\/SUP> macrophages within the immediate sprouting microenvironment. Blood 115:5053-5056, 2010","DOI":"10.1182\/blood-2009-11-253260"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, <I>et al<\/I>.: Ratio of M2 macrophage expression is closely associated with poor prognosis for angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 60:278-283, 2010","DOI":"10.1111\/j.1440-1827.2010.02514.x"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Steidl C, Lee T, Shah SP, Farinha P, Han G, <I>et al<\/I>.: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med 362:875-885, 2010","DOI":"10.1056\/NEJMoa0905680"},{"key":"49","unstructured":"49 Wada N, Zaki MA, Hori Y, Hashimoto K, Tsukaguchi M, <I>et al<\/I>.: Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. Histopathology 60:313-319, 2012"},{"key":"50","unstructured":"50 Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, <I>et al<\/I>.: Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120:3280-3287, 2012"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Komohara Y, Niino D, Saito Y, Ohnishi K, Horlad H, <I>et al<\/I>.: Clinical significance of CD163<SUP>+<\/SUP> tumor-associated macrophages in patients with adult T-cell leukemia\/lymphoma. Cancer Sci 104:945-951, 2013","DOI":"10.1111\/cas.12167"},{"key":"52","unstructured":"52 Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, <I>et al<\/I>.: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Murai M, Turovskaya O, Kim G, Madan R, Karp CL, <I>et al<\/I>.: Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nat Immunol 10:1178-1184, 2009","DOI":"10.1038\/ni.1791"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Mantovanin A, Sica A: Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22:231-237, 2010","DOI":"10.1016\/j.coi.2010.01.009"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:53Z","timestamp":1621540013000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/1\/54_49\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.49","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}